scispace - formally typeset
Search or ask a question
Institution

University of Southern Denmark

EducationOdense, Syddanmark, Denmark
About: University of Southern Denmark is a education organization based out in Odense, Syddanmark, Denmark. It is known for research contribution in the topics: Population & Randomized controlled trial. The organization has 11928 authors who have published 37918 publications receiving 1258559 citations. The organization is also known as: SDU.


Papers
More filters
Journal ArticleDOI
TL;DR: The present document updates previous guidelines released in 2006 and 2010 and states that percutaneous ethanol injection should be the first-line treatment option for relapsing, benign cystic lesions, while US-guided thermal ablation treatments may be considered for solid or mixed symptomatic benign thyroid nodules.

898 citations

Journal ArticleDOI
TL;DR: There are lessons to be learned from the current research conducted in countries where the prevalence of bullying is low that could be adapted for use in countries with higher prevalence.
Abstract: Objectives: (1) To compare the prevalence of bullying and victimization among boys and girls and by age in 40 countries. (2) In 6 countries, to compare rates of direct physical, direct verbal, and indirect bullying by gender, age, and country.

893 citations

BookDOI
01 Jan 2008
TL;DR: In this article, the authors introduce social network analysis, and present basic methods for analyzing networks, including data collection, basic methods, and advanced methods for analysing networks, such as clustering and clustering.
Abstract: Chapter 1. Introduction to Social Network Analysis Chapter 2. Network Fundamentals Chapter 3. Data Collection Chapter 4. Basic Methods for Analyzing Networks Chapter 5. Advanced Methods for Analyzing Networks References

889 citations

Journal ArticleDOI
16 Nov 2001-Cell
TL;DR: Using a cell-free RNA decay system, it is demonstrated that the mammalian exosome is required for rapid degradation of ARE-containing RNAs but not for poly(A) shortening.

884 citations

Journal ArticleDOI
TL;DR: Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma, and no maximum tolerated dose was identified in part 1.
Abstract: BACKGROUND Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1–2 trial involving patients with relapsed myeloma or relapsed myeloma that was refractory to two or more prior lines of therapy. METHODS In part 1, the dose-escalation phase, we administered daratumumab at doses of 0.005 to 24 mg per kilogram of body weight. In part 2, the dose-expansion phase, 30 patients received 8 mg per kilogram of daratumumab and 42 received 16 mg per kilogram, administered once weekly (8 doses), twice monthly (8 doses), and monthly for up to 24 months. End points included safety, efficacy, and pharmacokinetics. RESULTS No maximum tolerated dose was identified in part 1. In part 2, the median time since diagnosis was 5.7 years. Patients had received a median of four prior treatments; 79% of the patients had disease that was refractory to the last therapy received (64% had disease refractory to proteasome inhibitors and immunomodulatory drugs and 64% had disease refractory to bortezomib and lenalidomide), and 76% had received autologous stem-cell transplants. Infusion-related reactions in part 2 were mild (71% of patients had an event of any grade, and 1% had an event of grade 3), with no dose-dependent adverse events. The most common adverse events of grade 3 or 4 (in ≥5% of patients) were pneumonia and thrombocytope nia. The overall response rate was 36% in the cohort that received 16 mg per kilogram (15 patients had a partial response or better, including 2 with a complete response and 2 with a very good partial response) and 10% in the cohort that received 8 mg per kilogram (3 had a partial response). In the cohort that received 16 mg per kilogram, the median progression-free survival was 5.6 months (95% confidence interval [CI], 4.2 to 8.1), and 65% (95% CI, 28 to 86) of the patients who had a response did not have progression at 12 months. CONCLUSIONS Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma. (Funded by Janssen Research and Development and Genmab; ClinicalTrials.gov number, NCT00574288.)

882 citations


Authors

Showing all 12150 results

NameH-indexPapersCitations
Paul M. Ridker2331242245097
George Davey Smith2242540248373
Matthias Mann221887230213
Eric Boerwinkle1831321170971
Gang Chen1673372149819
Jun Wang1661093141621
Harvey F. Lodish165782101124
Jens J. Holst1601536107858
Rajesh Kumar1494439140830
J. Fraser Stoddart147123996083
Debbie A Lawlor1471114101123
Børge G. Nordestgaard147104795530
Oluf Pedersen135939106974
Rasmus Nielsen13555684898
Torben Jørgensen13588386822
Network Information
Related Institutions (5)
University of Copenhagen
149.7K papers, 5.9M citations

96% related

Lund University
124.6K papers, 5M citations

96% related

Utrecht University
139.3K papers, 6.2M citations

93% related

University of British Columbia
209.6K papers, 9.2M citations

93% related

University of Amsterdam
140.8K papers, 5.9M citations

93% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202382
2022410
20214,042
20203,614
20192,967
20182,603